Respiratory syncytial virus (RSV) vaccine! GSK Maternal Vaccine and Senior Vaccine Clinical Research: Rapidly Induce Strong Immunity!

October 22, 2020 // -- GlaxoSmithKline (GSK) recently announced that its respiratory syncytial virus (RSV) candidate vaccine is used in phase I/II studies for good tolerance and immunogenicity in maternal immunity (GSK3888550A vaccine) and elderly immunity (GSK3844766A vaccine).
RSV is the main cause of respiratory infections in infants, young children and the elderly, such as fine bronchitis (inflammation and congstation of the small airways or trachea of the lungs) and pneumonia (an inflammatory state of the small airbags or follicles in the lungs).
, RSV causes 3 million hospitalizations per year among children under 5 years of age, and in the United States, RSV causes 177,000 hospitalizations per year among older people.
two candidate vaccines contain recombinant sub-unit fusion pre-RSV antigens (RSVPreF3), which are believed to trigger the required immune response.
vaccines for the elderly also include GSK's proprietary AS01 adsition system to enhance the immune response, which tends to be weaker than in younger people.
The vaccine candidates for the elderly were first tested in 48 healthy adults (18-40 years of age) and then in 1,005 healthy older adults (60-80 years of age), using different doses of antigens and adoses and compared with placebos.
1 month after immunization: (1) candidate vaccines induced strong body fluids and cellular immunity compared to baselines; The increase was nearly tenfold; (3) importantly, in older adults who were vaccinated, cellular immunity (RSVPreF3-specific CD4-T cells) was enhanced to reach a range similar to that observed in young people, although the initial baseline levels observed in older adults were lower than in younger adults.
maternal immunology candidate vaccine was tested in 502 healthy non-pregnant women, and three different doses of RSV candidate vaccine were tested against a placebo for monthly visits (8, 31 and 91 days after immunization).
data show that compared to the baseline: (1) candidate vaccines can rapidly enhance existing immunity at all dose levels, resulting in high levels of protective neutrality antibodies;
The two vaccines are part of the GSK RSV vaccine program, which uses different new technologies to protect the most vulnerable: infants and the elderly, with three RSV candidate vaccines tailored to different populations (mother vaccine, childhood vaccine, elderly vaccine).
all three vaccine candidates have been approved by the FDA for fast-track (FTD).
vaccine against RSV can significantly reduce disease, hospitalization and hospitalization rates in infants, young children and the elderly, with significant implications for the health and medical costs of the world's most vulnerable populations.
Based on available data and contacts with regulators, Phase 3 studies of RSV candidate vaccines for the elderly and mothers are being prepared and are expected to start in the coming months, with phase I/II (RSV-negative infants) and Phase II (RSV sero-positive infants) studies still under way in children.
I/II safety and immunogenicity of RSV candidate vaccines in Serotony infants with RSV serotonies will be presented at the European Society of Pediatric Infectious Diseases (ESPID) meeting from 26 to 29 October 2020.
() Original origin: GSK presents positive clinical data on maternal and older adults RSV candidate vaccines